Psoriatic arthritis treatment and the riskof herpes zoster

Annals of the Rheumatic Diseases

Volumn 75, Issue 1, 2016, Pages 131-135

  Zisman, D ^a,b   Bitterman, H ^b,c   Shalom, G ^c   Feldhamer, I ^c   Comanesther, D ^c   Batat, E ^c   Greenberg Dotan, S ^c   Cohen, S ^a   Cohen, A D ^c,d  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c CLALIT HEALTH SERVICES   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; CYCLOSPORIN; DRUG COMBINATION; GLUCOSAMINE; ISOXAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RISK FACTOR; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; COMBINATION DRUG THERAPY; DRUG COMBINATION; MIDDLE AGED;

ADALIMUMAB; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; AZATHIOPRINE; CYCLOSPORINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; GLUCOSAMINE; HERPES ZOSTER; HUMANS; HYDROXYCHLOROQUINE; INCIDENCE; INFLIXIMAB; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84954309214     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-205148     Document Type: Article

References (31)

1. Pinchinat S, Cebrián-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013;13:170.
2. Smitten AL, Choi HK, Hochberg MC, et al. Clinical practice: herpes zoster. N Engl J Med 2002;347:340-6.
3. Dixon WG, Watson M, Lunt KL, et al. Rates of serious infection including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
4. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
5. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33.
6. Ito M, Nakano T, Kamiya T, et al. Effects of tumor necrosis factor alpha on replication of varicella-zoster virus. Antiviral Res 1991;15:183-92.
7. García-Doval I, Pérez-Zafrilla B, Descalzo MA, et al. BIOBADASER 2.0 Study Group: infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc) 2011;137:533-40.
8. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010;6:165-74.
9. Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013;72:229-34.
10. García-Doval I, Pérez-Zafrilla B, Descalzo MA, et al. BIOBADASER 2.0 Study Group: incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010;69:1751-5.
11. Failla V, Jacques J, Castronovo C, et al. Herpes zoster in patients treated with biologicals. Dermatol 2012;224:251-6.
12. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
13. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009;48:1364-71.
14. Dreiher J, Kresch FS, Comaneshter D, et al. Risk of Herpes zoster in patients with psoriasis treated with biologic drugs. J Eur Acad Dermatol Venereol 2012;26:1127-32.
15. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309:887-95.
16. Salmon-Ceron D, Tubach F, Lortholary O, et al. RATIO group: Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616-23.
17. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 2000;356:385-90.
18. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab effectiveness in psoriatic arthritis trial study group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
19. Wohl Y, Dreiher J, Cohen AD. Pemphigus and osteoporosis: a case-control study. Arch Dermatol 2010;146:1126-31.
20. Cohen AD, Weitzman D, Birkenfeld S, et al. Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology 2010;220:218-22.
21. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82.
22. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007;57:1431-8.
23. Che H, Lukas C, Morel J, et al. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine 2014;81:215-21.
24. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010;69:380-6.
25. Perez-Zafrilla B, García Doval I, Carmona L. Rates of herpes zoster in patients with rheumatoid arthritis and treatment with TNF antagonists. Incidence rate in BIOBADASER cohort in comparison with EMECAR cohort. Ann Rheum Dis 2008;67:327 [abstract FRI0129].
26. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
27. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006;45:1370-5.
28. Sakai R, Komano Y, Tanaka M, et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res 2012;64:1125-34.
29. Gnann JW Jr, Whitley RJ. Clinical practice: Herpes zoster. New Engl J Med 2002;347:340-6.
30. Serac G, Tubach F, Mariette X, et al. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry. J Invest Dermatol 2012;132(3 Pt 1):726-9.
31. Harpaz R, Ortega-Sanchez IR, Seward JF, et al. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57:1-30.